Albert Lowe
Stock Analyst at Craig-Hallum
(3.21)
# 872
Out of 5,180 analysts
10
Total ratings
40%
Success rate
34.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Buy | $175 | $120.38 | +45.37% | 1 | Dec 4, 2025 | |
| NGNE Neurogene | Initiates: Buy | $50 | $21.66 | +130.84% | 1 | Jun 17, 2025 | |
| ATOS Atossa Therapeutics | Initiates: Buy | $20 | $5.11 | +291.39% | 1 | Jun 5, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $6 | $4.69 | +27.93% | 1 | Apr 11, 2025 | |
| SKYE Skye Bioscience | Maintains: Buy | $18 → $14 | $0.66 | +2,005.58% | 2 | Mar 21, 2025 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $11 | $3.87 | +184.24% | 1 | Oct 9, 2024 | |
| CRDF Cardiff Oncology | Initiates: Buy | $8 | $1.61 | +396.89% | 1 | Sep 6, 2024 | |
| LCTX Lineage Cell Therapeutics | Initiates: Buy | $4 | $1.59 | +151.57% | 1 | Aug 20, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $6 | $1.35 | +346.10% | 1 | May 13, 2024 |
Palvella Therapeutics
Dec 4, 2025
Initiates: Buy
Price Target: $175
Current: $120.38
Upside: +45.37%
Neurogene
Jun 17, 2025
Initiates: Buy
Price Target: $50
Current: $21.66
Upside: +130.84%
Atossa Therapeutics
Jun 5, 2025
Initiates: Buy
Price Target: $20
Current: $5.11
Upside: +291.39%
Opus Genetics
Apr 11, 2025
Initiates: Buy
Price Target: $6
Current: $4.69
Upside: +27.93%
Skye Bioscience
Mar 21, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $0.66
Upside: +2,005.58%
SAB Biotherapeutics
Oct 9, 2024
Initiates: Buy
Price Target: $11
Current: $3.87
Upside: +184.24%
Cardiff Oncology
Sep 6, 2024
Initiates: Buy
Price Target: $8
Current: $1.61
Upside: +396.89%
Lineage Cell Therapeutics
Aug 20, 2024
Initiates: Buy
Price Target: $4
Current: $1.59
Upside: +151.57%
PMV Pharmaceuticals
May 13, 2024
Initiates: Buy
Price Target: $6
Current: $1.35
Upside: +346.10%